Table 1:
Patient characteristics (NoD versus IND).
| No dysplasia (n=359) |
Indefinite dysplasia (n=53) |
p value | |
|---|---|---|---|
| Baseline Characteristics | |||
| Age (y), mean (SD) | 40.5 (14.9) | 44.5 (14.9) | 0.07 |
| Male Sex, n (%) | 181 (50.4) | 32 (60.4) | 0.18 |
| IBD-type, n (%) | |||
| UC | 185 (51.5) | 30 (56.6) | |
| CD | 161 (44.8) | 19 (35.8) | |
| IBDU | 13 (3.6) | 4 (7.5) | 0.25 |
| PSC, n (%) | 73 (20.3) | 17 (32.1) | 0.053 |
| Disease duration (y), median (IQR) | 11.6 (8.5 – 20.4) | 12.6 (8.7 – 21.1) | 0.46 |
| Extensive colitis, n (%) | 180 (50.1) | 39 (73.6) | 0.001* |
| Family history of CRC, n (%) | 14 (3.9) | 3 (5.7) | 0.47 |
| Medication exposure, n (%) |
|||
| Biologicals | 167 (46.5) | 22 (41.5) | 0.50 |
| Immunomodulators | 217 (60.4) | 35 (66.0) | 0.43 |
| 5-Aminosalicylates | 317 (88.3) | 45 (84.9) | 0.48 |
| Colonoscopic Surveillance Details | |||
| Duration of follow-up (y), mean (SD) | 4.2 (2.5) | 5.8 (3.4) | <0.0005* |
| Number of adequate surveillance colonoscopies, median (IQR) | 2.0 (2.0 – 3.0) | 3.0 (2.0 – 6.0) | 0.006* |
| Average number of biopsy jars per procedure, median (IQR) | 7.3 (5.5 – 8.6) | 8.1 (7.3 – 9.4) | <0.0005* |
| Interval between surveillance colonoscopies (y), median (IQR) | 1.24 (0.82 – 1.61) | 0.94 (0.68 – 1.27) | 0.03* |
| Procedures with chromoendoscopy, n (% of total number of procedures per group) | 29 (2.5) | 20 (6.4) | <0.0005* |
| Mean Histologic inflammation, mean (SD) | 2.9 (0.9) | 3.4 (1.0) | <0.001* |
*
Significant at p<0.05.